Jason Smith - UroGen Pharma Chief Counsel
| URGN Stock | USD 12.02 0.36 3.09% |
Insider
Jason Smith is Chief Counsel of UroGen Pharma
| Age | 52 |
| Address | 400 Alexander Park Drive, Princeton, NJ, United States, 08540 |
| Phone | 646 768 9780 |
| Web | https://www.urogen.com |
Jason Smith Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jason Smith against UroGen Pharma stock is an integral part of due diligence when investing in UroGen Pharma. Jason Smith insider activity provides valuable insight into whether UroGen Pharma is net buyers or sellers over its current business cycle. Note, UroGen Pharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell UroGen Pharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jason Smith few days ago Disposition of 3800 shares by Jason Smith of UroGen Pharma at 18.01 subject to Rule 16b-3 | ||
Jason Smith over a month ago Disposition of 6667 shares by Jason Smith of UroGen Pharma subject to Rule 16b-3 | ||
Jason Smith over six months ago Disposition of 417 shares by Jason Smith of UroGen Pharma at 15.78 subject to Rule 16b-3 | ||
Jason Smith over six months ago Acquisition by Jason Smith of 833 shares of UroGen Pharma subject to Rule 16b-3 |
UroGen Pharma Management Efficiency
The company has return on total asset (ROA) of (0.2578) % which means that it has lost $0.2578 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (14.8126) %, meaning that it created substantial loss on money invested by shareholders. UroGen Pharma's management efficiency ratios could be used to measure how well UroGen Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 20th of March 2025, Return On Equity is likely to grow to 15.13, while Return On Tangible Assets are likely to drop (0.47). At this time, UroGen Pharma's Total Assets are very stable compared to the past year. As of the 20th of March 2025, Other Current Assets is likely to grow to about 10.4 M, though Net Tangible Assets are likely to grow to (97.6 M).Similar Executives
| Showing other executives | INSIDER Age | ||
| Brian Sullivan | Celcuity LLC | 63 | |
| Daniel Bensen | Tyra Biosciences | 49 | |
| Allison Talbot | PureTech Health PLC | N/A | |
| Hiroomi MD | Tyra Biosciences | 60 | |
| Zoology Dphil | Ovid Therapeutics | 69 | |
| Michael Carruthers | Edgewise Therapeutics | 67 | |
| Nathanael Gray | C4 Therapeutics | N/A | |
| MPH MD | Connect Biopharma Holdings | 54 | |
| Andrew Hirsch | C4 Therapeutics | 53 | |
| Kristine Rosse | Protara Therapeutics | N/A | |
| Wei MD | Erasca Inc | 54 | |
| SPHR SHRMSCP | Ovid Therapeutics | N/A | |
| Marni Kottle | Kronos Bio | N/A | |
| Lauren White | C4 Therapeutics | N/A | |
| MBA MD | Scholar Rock Holding | 57 | |
| Stewart Fisher | C4 Therapeutics | 57 | |
| Nik Chetwyn | Erasca Inc | N/A | |
| James McArthur | PepGen | 63 | |
| Joshua Kazam | Kronos Bio | 48 | |
| Sheri Smith | Celcuity LLC | N/A | |
| Michelle Zhang | Ikena Oncology | N/A | |
Management Performance
| Return On Equity | -14.81 | ||||
| Return On Asset | -0.26 |
UroGen Pharma Leadership Team
Elected by the shareholders, the UroGen Pharma's board of directors comprises two types of representatives: UroGen Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UroGen. The board's role is to monitor UroGen Pharma's management team and ensure that shareholders' interests are well served. UroGen Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UroGen Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dong Kim, Chief Officer | ||
| Jason JD, Chief Counsel | ||
| Sari PrutchiSagiv, Marketing Director | ||
| Jason Smith, Chief Counsel | ||
| Bryon Wornson, Advocacy Talent | ||
| Eric Zanten, Director Communications | ||
| Christopher CPA, Chief Officer | ||
| MD MPH, Senior Development | ||
| James Rph, Executive Quality | ||
| Vincent Perrone, Director Relations | ||
| DVM MBA, Chief Officer | ||
| Marina Konorty, Executive Operations | ||
| Gil Hakim, Consultant | ||
| Mark MD, Chief Officer | ||
| David Lin, Chief Officer | ||
| Christopher Degnan, Chief Officer | ||
| Ron MBA, Advisor | ||
| Elizabeth Barrett, President CEO, Director | ||
| Jeffrey MBA, Chief Officer |
UroGen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is UroGen Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -14.81 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (1.40) % | ||||
| Operating Margin | (1.08) % | ||||
| Current Valuation | 424.16 M | ||||
| Shares Outstanding | 46.09 M | ||||
| Shares Owned By Insiders | 8.40 % | ||||
| Shares Owned By Institutions | 86.93 % | ||||
| Number Of Shares Shorted | 6.19 M | ||||
| Price To Earning | 239.57 X |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share | Quarterly Revenue Growth 0.044 | Return On Assets | Return On Equity |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.